Eye Gene아이진
185490 · KOSDAQ · ₩185490 · 아이진
₩1,705▼ ₩45 (2.57%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 27.8% | 31.3% | 34.5% | 60.4% | 51.9% | 46.4% |
| Operating margin | −276.2% | −276.2% | −395.0% | −866.6% | −455.1% | −1,079.7% |
| Net margin | −391.5% | −440.3% | −361.4% | −717.7% | −500.4% | −1,066.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +25.7% | +6.3% | +7.4% | −41.0% | +63.3% | — |
| Operating income growth | −25.7% | +25.7% | +51.1% | −12.4% | +31.2% | — |
| Net income growth | −11.8% | −29.5% | +45.9% | +15.3% | +23.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −32.7% | −29.2% | −21.4% | −33.9% | −33.5% | −38.9% |
| Return on assets | −32.5% | −28.6% | −18.0% | −28.3% | −28.6% | −32.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 30.1% | 25.4% | 28.5% | 21.4% | 16.6% | 18.0% |
| Net debt to equity | −75.1% | −74.1% | −60.5% | −83.7% | −0.9% | 0.4% |
| Current ratio | 397.0% | 476.3% | 320.9% | 932.7% | 1,399.1% | 922.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Eye Gene / 아이진 / 185490 / KRX:185490
Source: KRX statistical information